2019’s second unicorn Gossamer raises $276M in upsized IPO offering, MGM’s Harpoon makes its Nasdaq debut with $75.6M bounty

February 8, 2019 sandiegobiotech News Comments Off on 2019’s second unicorn Gossamer raises $276M in upsized IPO offering, MGM’s Harpoon makes its Nasdaq debut with $75.6M bounty

Meet 2019?s newest biotech unicorn ? Gossamer Bio ??which is making its debut on Nasdaq Friday with an upsized $276 million offering.

The drug developer ? with a valuation of $1 billion, according to Renaissance Capital ? is run by former Receptos executives, and follows the year?s first unicorn Alector?$ALEC that raised?$176 million?at a $19 midpoint price. Investors are eagerly anticipating the performance of both, with an eye on other IPO?s waiting in line, after a turbulent December ravaged stocks across the boar

Related Articles

No Picture

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

January 6, 2019 sandiegobiotech Uncategorized Comments Off on Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their claim with a new-and-improved BCMA CAR-T therapy?
Poseida Therapeutics is aiming to find that out in the very near future… […]